Baillie Gifford & CO Denali Therapeutics Inc. Transaction History
Baillie Gifford & CO
- $127 Billion
- Q4 2024
A detailed history of Baillie Gifford & CO transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Baillie Gifford & CO holds 12,313,931 shares of DNLI stock, worth $287 Million. This represents 0.2% of its overall portfolio holdings.
Number of Shares
12,313,931
Previous 13,345,887
7.73%
Holding current value
$287 Million
Previous $389 Million
35.45%
% of portfolio
0.2%
Previous 0.3%
Shares
29 transactions
Others Institutions Holding DNLI
# of Institutions
226Shares Held
119MCall Options Held
60.6KPut Options Held
48.4K-
Black Rock Inc. New York, NY13.2MShares$307 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.2MShares$260 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA10.7MShares$250 Million0.06% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.91MShares$184 Million0.05% of portfolio
-
Temasek Holdings (Private) LTD Singapore, U05.36MShares$125 Million0.64% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $3.13B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...